Effect of probiotics on allergic rhinitis in Df, Dp or dust-sensitive children: A randomized double blind controlled trial
- First Online:
- 122 Downloads
To study, we examined the effect of Lactobacillus salivarius on the clinical symptoms and medication use among children with established allergic rhinitis (AR).
Double blind, randomized, controlled trial.
Hualien Tzu-Chi General Hospital.
Atopic children with current allergic rhinitis received 4 × 109 colony forming units/g of Lactobacillus salivarius (n=99) or placebo (n=100) daily as a powder mixed with food or water for 12 weeks. The SCORing Allergic rhinitis index (specific symptoms scores [SSS] and symptom medication scores [SMS]), which measures the extent and severity of AR, was assessed in each subject at each of the visits — 2 weeks prior to treatment initiation (visit 0), at the beginning of the treatment (visit 1), then at 4 (visit 2), 8 (visit 3) and 12 weeks (visit 4) after starting treatment. The WBC, RBC, platelet and, eosinophil counts as well as the IgE antibody levels of the individuals were evaluated before and after 3 months of treatment.
The major outcome, indicating the efficacy of Lactobacillus salivarius treatment, was the reduction in rhinitis symptoms and drug scores. No significant statistical differences were found between baseline or 12 weeks in the probiotic and placebo groups for any immunological or blood cell variables.
Our study demonstrates that Lactobacillus salivarius treatment reduces rhinitis symptoms and drug usage in children with allergic rhinitis.
Unable to display preview. Download preview PDF.
- 2.Krishna MT, Mavroleon G, Holgate ST. Essentials of Allergy. London: Martin Dunitz; 2001: 107–127.Google Scholar
- 3.Havenaar R, Huis in’t Veld JHJ. Probiotics: a general view. The lactic acid bacteria. In: Wood BJB, Ed. The Lactic Acid Bacteria in Health and Disease. London: Elsevier Applied Science. 1992;1:151–171.Google Scholar
- 4.Bjorksten B, Naaber P, Sepp E, Mikelsaar M. The intestinal microflora in alergic Estonian and Swedish 2-year-old children. Clin Exp Immunol. 1999;29:342–346.Google Scholar
- 14.La Rosa M, Ranno C, Andrè C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardizaed Parietaria Judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 1999;104:425–432.PubMedCrossRefGoogle Scholar
- 15.Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-g- and interleukin-10-production. Clin Exp Allergy. 2006; 36:261–272.PubMedCrossRefGoogle Scholar
- 17.Di’az-Ropero MP, Marti’n R, Sierra S, Lara-Villoslada F, Rodríguez JM, Xaus J, et al. Two Lactobacillus strains, isolated from breast milk, differently modulate the immune response. J Appl Microbiol. 2007;102:337–343.Google Scholar
- 23.Xiao JZ, Kondo S, Yanagisawa N, Takahashi N, Odamaki T, Iwabuchi N, et al. Effect of probiotic Bifidobacteriu mlongum BB536 in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season: a randomized doubleblind, placebo-controlled trial. J Investig Allergol Clin Immunol. 2006;16:86–93.PubMedGoogle Scholar